Patent classifications
C12N2500/14
SERUM-FREE MEDIUM FOR FULL SUSPENSION CULTURE OF MDCK CELLS AND PREPARATION METHOD OF SERUM-FREE MEDIUM
The present invention discloses a serum-free medium for full suspension culture of MDCK cells and a preparation method of the serum-free medium. The serum-free medium for full suspension culture of the MDCK cells comprises basic metabolic nutrients, nucleotide, vitamins, inorganic salts, a shear force protective agent, a cell clustering resisting agent, a pH buffer agent, a pH indicator, an influenza virus proliferation accelerant and other additives. The preparation method of the serum-free medium for the full suspension culture of the MDCK cells comprises the following steps: 1) preparing a mixed solution: dissolving and mixing raw materials; and 2) regulating pH: regulating the pH of the mixed solution to 6.3 to 6.7, and setting a constant volume to obtain the serum-free medium for the full suspension culture of the MDCK cells. The medium supports the high-density full-suspension culture of the MDCK single cells, greatly shortens a time for educating the MDCK cells from adherent cells into the serum-free full suspension cells, and is applicable to the mass production of biological products, and particularly veterinary biological products.
COMPOSITIONS AND METHODS FOR BIOENGINEERED TISSUES
The present disclosure provides methods for producing bioengineered tissue along with an apparatus and other relevant compositions employed in generation thereof.
METHOD FOR CONTROLLED PRODUCTION OF GLYCERIC ACID
A method for controlled production of glyceric acid includes, during the glyceric acid fermentation process, real-time online monitoring of at least one of the respiratory quotient and redox potential in the fermentation liquid as well as the fermentation process specific growth rate, and controlling their values within the following ranges: 0.1˜1.5 for respiratory quotient, −300˜50 mV for redox potential, 0.05˜0.8 for specific growth rate. Process parameters for this method are controlled within predetermined ranges by online monitoring at least one of respiratory quotient (RQ) and redox potential as well as the specific growth rate in the fermentation process, thereby meeting the growth requirements of bacteria, effectively promoting the glycerol metabolism and synthesis and improving the conversion rate.
Process for the Manufacturing of Protein-Associated Extracellular Vesicles
The current invention relates to a process for the manufacturing of extracellular vesicles (EVs) associated with proteins, derived from mesenchymal stromal cells (MSCs), said process comprises the steps of: - Purifying EVs from a cell medium comprising MSCs, wherein said purifying occurs via at least one filtration step of said medium; followed by - a concentration step of the filtrate of said at least one filtration step, wherein said EVs are concentrated by means of tangential flow filtration in a TFF device; and - wherein during said TFF step the EVs are associated with one or more exogenous proteins inside of said TFF device, or in a vessel fluidly connected to said TFF device to which said EVs are transferred from said TFF. The current invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of EVs associated with proteins, and the use thereof.
COSMETIC COMPOSITION FOR IMPROVING CONDITION OF SKIN, CONTAINING CELL CULTURE MEDIUM, EPIDERMAL GROWTH FACTOR AND BOVINE SERUM ALBUMIN
The present invention relates to: a cosmetic composition for improving the condition of the skin, containing, as active ingredients, a cell culture medium, an epidermal growth factor and a bovine serum albumin; a method for improving the condition of the skin by using the same; and a method for preventing or treating skin diseases. According to the present invention, the cosmetic composition can exhibit excellent wrinkle-reducing and wound-healing effects even when only a small amount of EGF is used, and thus can be useful in improving the condition of the skin or in preventing or treating skin diseases.
Ex vivo proliferation of epithelial cells
The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.
Pluripotent cells
Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration.
Method for preparation of fungal mutant with high hydrolytic activity
A method for preparing a hyper-cellulolytic catabolite derepressed mutants of ascomycetes fungus, especially variants of Penicillium funiculosum. Selection media used to isolate such variants include amorphous cellulose and a high concentration of glucose. Cellulase activities of mutant ID-10, in particular such as FPase and β-glucosidase were 1.5 times higher than Penicillium funiculosum MRJ-16 (parent). Furthermore, fungal mutant morphology was changed and no pH adjustment was required throughout the enzyme production process.
MEDIUM COMPOSITION FOR CULTURING STEM CELLS
The present disclosure relates to a medium composition for culturing stem cells, and more specifically, to a medium composition for culturing mesenchymal stem cells, in which the medium composition includes a basic medium in which various quasi-completed mediums (DMEM, α-MEM, IMDM, F12, and DMEM/F12) are mixed, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factors (b-FGF), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone.
According to the present disclosure, it is capable of improving proliferation ability and differentiation ability of the mesenchymal stem cells, and is capable of producing cell therapy products more economically using the mesenchymal stem cells by enabling the mesenchymal stem cells to be cultured at a low price compared to the existing culturing methods.
CULTURE MEDIA FOR MULTIPOTENT STEM CELLS
A culture medium for human adipose tissue derived mesenchymal stem cells includes a keratinocyte-SFM basal medium, L-Cysteine, FGF and SDF-1 is disclosed. The culture medium is effective for growing mesenchymal stem cells at a high proliferation rate while maintaining the purity, characterization and undifferentiated state of the cells.